Six days after a startling trial halt, AstraZeneca gets a green light to resume dosing their Oxford Covid-19 vaccine
Six days after an abrupt and startling halt of their late-stage study of the Oxford vaccine for Covid-19, AstraZeneca is back in business. And we also learned on Saturday that Pfizer and BioNTech are boosting the size of their fast-running Phase III, with plans to add 14,000 people to the study to provide a more diverse group to test.
AstraZeneca put out a statement Saturday that UK regulators had offered a green light to start dosing again after concluding that it was safe for volunteers to take it. But the multinational player is not offering any detailed information about the severe adverse event that stopped the study, triggering headlines around the globe.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.